Under the deal, Cencora will be responsible for distributing the Sapphiros’ GoToKnow Covid-19 Antigen Rapid Tests to pharmacies in the US.
Sapphiros expects the strategic partnership to improve accessibility and convenience for patients looking to purchase reliable Covid-19 testing solutions.
The GoToKnow rapid antigen test, authorised by the US Food and Drug Administration only for the detection of proteins from SARS-CoV-2, is developed to allow users to take test at home.
It provides results in 15 minutes for the identification of the SARS-CoV-2 nucleocapsid protein antigen.
During the acute infection phase, this antigen is generally detectable in anterior nasal swab specimens.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
Your download email will arrive shortly
We are confident about the
quality of our Company Profiles. However, we want you to make the most
decision for your business, so we offer a free sample that you can download by
submitting the below form
Cencora will also have access to the future technologies of Sapphiros, including additional rapid lateral flow tests for diseases beyond Covid-19, a fully disposable, low-cost multiplexed molecular diagnostics platform, and the Satio blood collection patch planned to be launched early next year.
Sapphiros CEO Mark Gladwell said: “This is a significant milestone for our company and further validates Sapphiros’s unique and transformational technologies.
“We are honoured to partner with Cencora to bring this product as well as future innovative product offerings directly to patients across the US enabling the consumer to directly access their diagnostic results and manage their health.”
Backed by KKR and Neoenta, Sapphiros has a portfolio of capabilities and technologies such as novel sample collection, next-generation diagnostics, computational biology, and printed electronics.